Furthermore, high‐TIL surrounding DCIS foci might thus collaborate with anti‐HER2 therapies and immunotherapies to aid the clearance of HER2‐positive DCIS. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.